Cerebrovascular autoregulation and arterial carbon dioxide in patients with acute respiratory distress syndrome: a prospective observational cohort study

Ursula Kahl1†, Yuanyuan Yu1†, Axel Nierhaus2, Daniel Frings2, Barbara Sensen2, Anne Daubmann3, Stefan Kluge2 and Marlene Fischer1,2*

Abstract

Background: Early hypercapnia is common in patients with acute respiratory distress syndrome (ARDS) and is associated with increased mortality. Fluctuations of carbon dioxide have been associated with adverse neurological outcome in patients with severe respiratory failure requiring extracorporeal organ support. The aim of this study was to investigate whether early hypercapnia is associated with impaired cerebrovascular autoregulation during the acute phase of ARDS.

Methods: Between December 2018 and November 2019, patients who fulfilled the Berlin criteria for ARDS, were enrolled. Patients with a history of central nervous system disorders, cerebrovascular disease, chronic hypercapnia, or a life expectancy of less than 24 h were excluded from study participation. During the acute phase of ARDS, cerebrovascular autoregulation was measured over two time periods for at least 60 min. Based on the values of mean arterial blood pressure and near-infrared spectroscopy, a cerebral autoregulation index (COx) was calculated. The time with impaired cerebral autoregulation was calculated for each measurement and was compared between patients with and without early hypercapnia [defined as an arterial partial pressure of carbon dioxide (PaCO2) ≥ 50 mmHg with a corresponding arterial pH < 7.35 within the first 24 h of ARDS diagnosis].

Results: Of 66 patients included, 117 monitoring episodes were available. The mean age of the study population was 58.5 ± 16 years. 10 patients (15.2%) had mild, 28 (42.4%) moderate, and 28 (42.4%) severe ARDS. Nineteen patients (28.8%) required extracorporeal membrane oxygenation. Early hypercapnia was present in 39 patients (59.1%). Multivariable analysis did not show a significant association between early hypercapnia and impaired cerebrovascular autoregulation (β = 0.023 [95% CI − 0.054; 0.100], p = 0.556). Hypocapnia during the monitoring period was significantly associated with impaired cerebrovascular autoregulation [β = 0.155 (95% CI 0.014; 0.296), p = 0.032].

Conclusion: Our results suggest that moderate permissive hypercapnia during the acute phase of ARDS has no adverse effect on cerebrovascular autoregulation and may be tolerated to a certain extent to achieve low tidal volumes. In contrast, episodes of hypocapnia may compromise cerebral blood flow regulation.

Trial registration ClinicalTrials.gov; registration number: NCT03949738; date of registration: May 14, 2019

*Correspondence: mar.fischer@uke.de
†Ursula Kahl and Yuanyuan Yu authors contributed equally to the study
1 Department of Anesthesiology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
Full list of author information is available at the end of the article
Background
The acute respiratory distress syndrome (ARDS) is a respiratory failure of acute onset, characterized by bilateral pulmonary opacities and severe hypoxemia that cannot be fully explained by cardiac failure or fluid overload [1]. ARDS is common in the intensive care unit (ICU) accounting for about 10% of ICU admissions [2]. Despite advances in the management of ARDS, the mortality remains high with up to 46% in severe ARDS [2]. ARDS survivors suffer from long-term physical disability and cognitive impairment [3].

To allow for low tidal volumes and to avoid ventilator-induced lung injury, the concept of permissive hypercapnia has been proposed in the 1990s [4]. Lower tidal volumes with a moderate hypercapnic acidosis have been shown to improve outcome after ARDS [5]. However, controversy remains on the effects of hypercapnia in ARDS owing to the results of numerous experimental studies suggesting impaired immunological, alveolar epithelial, and hemodynamic function [6–8]. A secondary analysis of three prospective observational trials showed increased ICU mortality in patients with ARDS and early hypercapnia [9]. Aside from hypercapnia, fluctuations of carbon dioxide (CO₂), have been associated with life-threatening neurological complications in patients requiring extracorporeal membrane oxygenation (ECMO) [10]. Importantly, CO₂ is one of the most potent vasoactive substances acting on the cerebral circulation, with hypercapnia leading to vasodilation and hypocapnia inducing vasoconstriction [11].

Cerebral blood flow is tightly regulated by autoregulation of the cerebral circulation to ensure a continuous supply of oxygen and nutrients meeting the high cerebral metabolic demand [12]. Cerebrovascular autoregulation (CVA) mediates vasodilation in response to hypotension to avoid cerebral hypoperfusion with the risk of ischemia [13]. In contrast, CVA induces vasoconstriction in response to hypertension to prevent cerebral hyperperfusion [13]. Importantly, there is considerable inter- and intradividual variation in the upper and lower thresholds of CVA, depending, amongst others, on chronic changes of the cerebral vasculature, the influence of anesthetics, fluctuations in PaCO₂, and various other mechanisms [13]. Impaired CVA has been observed in critically ill patients and is associated with adverse neurocognitive outcome [14–16].

The aim of this study was to investigate whether early hypercapnia is associated with impaired CVA during the acute phase of ARDS.

Materials and methods
Study registration and ethical information
Ethical approval for this study (serial number PV5872) was obtained from the ethics committee of the Hamburg Chamber of Physicians on November 8th, 2018. Oral and written informed consent were obtained from the patient or legal guardian. Details on the informed consent procedure are provided in Additional file 1.

Design, setting, and participants
This prospective substudy is part of an observational cohort study that follows two aims: (1) to investigate whether early hypercapnia is associated with impaired CVA during the acute phase of ARDS; (2) to assess the association between impaired CVA and self-reported cognitive failures and health-related quality of life. We enrolled patients between December 2018 and November 2019. Adult patients, who were treated for ARDS according to the Berlin definition at the Department of Intensive Care Medicine of the University Medical Center Hamburg-Eppendorf, were screened for eligibility [1]. Patients with a history of central nervous system disorders, cerebrovascular disease, chronic hypercapnia, or a life expectancy of less than 24 h were excluded.

ARDS management
Patients with moderate or severe hypoxemic respiratory failure refractory to high-flow oxygen or non-invasive ventilation were intubated and mechanically ventilated according to current guidelines and institutional standard operating procedures [17, 18]. Permissive hypercapnia was accepted as long as the arterial pH was higher than 7.2 to ensure lung-protective ventilation with tidal volumes of max. 6 ml/kg of ideal body weight (IBW).

Adjunctive therapies included proning, administration of inhalational nitric oxide, and veno-venous ECMO (vv-ECMO) and were applied according to international and national guidelines [17, 19, 20]. Details on ARDS management throughout the study period are described in Additional file 1.
Definition of hypercapnia
Early hypercapnia at ARDS onset was defined as arterial partial pressure of CO₂ (PaCO₂) ≥ 50 mmHg with a corresponding pH < 7.35 within the first 24 h of ARDS diagnosis. The cut-off for hypercapnia was chosen according to Nin et al., who had shown that a PaCO₂ ≥ 50 mmHg within the first 48 h of mechanical ventilation was significantly associated with higher mortality [9].
PaCO₂ during measurement refers to the mean value of two blood gas analyses performed at the beginning and at the end of each CVA monitoring period. PaCO₂ values were categorized as “normocapnia” (35–50 mmHg), “hypocapnia” (< 35 mmHg), and “hypercapnia” (> 50 mmHg).

Monitoring of cerebrovascular autoregulation
During the acute phase of ARDS, i.e. within the first 6 days of diagnosis, CVA was measured twice with a minimum interval of 24 h between measurements [21]. Each measurement period had a duration of 60–90 min. CVA was measured during stable respiratory status: one member of the study team supervised the measurement and ensured that ventilation settings (FiO₂, respiratory rate, inspiratory pressure, positive end-expiratory pressure) were not changed from 30 min before CVA monitoring until measurement completion. If ventilation settings had to be changed for clinical reasons, the measurement was interrupted and resumed later. In patients with vv-ECMO, the CVA measurement was not started until at least 5 h after the beginning of vv-ECMO therapy. For the monitoring of CVA, we used the time correlation method which has been described in detail previously [22–24]. In brief, the cerebral oxygenation index (COx) is calculated from mean arterial pressure (MAP) and cerebral oxygenation (rSO₂). The MAP was measured continuously with an intra-arterial catheter (Leader-Cath, VYGON GmbH & Co KG, Aachen, Germany) placed in the radial or femoral arteries. Cerebral oxygenation was measured non-invasively with near-infrared spectroscopy (INVOS™ 5100 Cerebral Oximeter, Medtronic, Minneapolis, Minnesota). From the MAP and rSO₂ values, the COx was depicted as a moving linear correlation coefficient based on a sliding 300-s window that was updated every 10 s (ICM+, Cambridge Enterprise, Cambridge, UK). A COx close to zero indicates intact CVA. In contrast, a positive correlation between rSO₂ and MAP indicates impaired CVA. COx levels > 0.3 are considered as an indicator of a pathological cerebrovascular autoregulatory response to systemic blood pressure fluctuations [25]. The time with impaired CVA was defined as the percentage of the total monitoring time with a cerebral oxygenation index COx ≥ 0.3.

Power calculation
We hypothesized that CVA would be more impaired in patients with early hypercapnia compared with patients without early hypercapnia. We aimed to analyze a consecutive sample of patients with ARDS over a 12-month period. Assuming a type I error of 5% (two-tailed hypothesis) and a power of 80%, a sample size of 50 patients would be sufficient to achieve an effect size of 0.81. With a standard deviation of 0.21, a mean difference of 0.17 in COx between groups would be statistically significant. This difference is considered as clinically relevant. We used PASS Version 15.0.3, module “Two-Sample t-Tests using Effect Size” (NCSS, LLC. Kaysville, Utah, USA).

Statistical analysis
For descriptive statistics, mean and standard deviation or total numbers with percentages were used. Baseline demographic and clinical characteristics were compared between patients with and without early hypercapnia with the Chi-square test, Fisher’s exact test, or Mann–Whitney-U test as appropriate. Patients who died before informed consent was obtained were not considered in the statistical analysis. Patients who died before the second monitoring episode were included in the analysis.

For statistical evaluation of association between early hypercapnia and impaired CVA, a linear mixed model fit by restricted maximum likelihood was built including the dependent variable (relative time with impaired CVA), the independent variable of primary interest (early hypercapnia vs. no early hypercapnia) and clinically relevant variables with potential confounding influence (age, Sequential Organ Failure Assessment score, ARDS severity, ARDS etiology, sedation, PaCO₂ during CVA assessment, prone position, inhalational nitric oxide, vv-ECMO) as fixed effects and patient as a random effect. The model was gradually reduced following a stepwise-backwards approach. Variables that caused a change in parameter estimates of > 10% or that were statistically significant (p < 0.05, two-tailed hypotheses) remained in the model. The linearity between continuous variables was checked graphically with scatter plots. Residuals
were graphically assessed for normal distribution using Q–Q and residual plots. Additionally, we performed a leave-one-out cross-validation to evaluate the final model. As part of a sensitivity analysis, the model was recalculated with (1) a higher threshold for early hypercapnia (PaCO₂ ≥ 60 mmHg with a corresponding pH < 7.35 within the first 24 h of ARDS diagnosis) and (2) delta PaCO₂ (the difference between ARDS diagnosis and CVA assessment).

An exploratory subgroup analysis was performed to compare CVA during measurements with and without vv-ECMO. In patients, who received vv-ECMO between two measurements, CVA was compared before and after vv-ECMO initiation.

All statistical analyses were performed with SPSS Version 24 (IBM SPSS Statistics, IBM Corporation). Figures were designed with Prism 8, Version 8.4.3 (GraphPad Software Inc., San Diego, CA, USA).

**Results**

**Patient characteristics**

Between December 2018 and November 2019, 70 patients were enrolled and 66 patients were included in the final analysis. Data from 2 patients, who died before a legal guardian was appointed or before they regained consciousness and ability to give informed consent, were destroyed and therefore not available for analysis. Legal guardians from two patients did not give consent to study.
participation. Data from the remaining patients were collected completely, so there are no missing values in our dataset. Figure 1 shows the flow of participants throughout the study.

The mean age of the study population was 58.5 years (±16); 14 patients (21.2%) were female. The majority of patients fulfilled the criteria for moderate (n=28, 42.4%) or severe (n=28; 42.4%) ARDS. PaO₂/FiO₂ ratios and PEEP values for individual study participants are presented in Additional file 2. Etiologies of ARDS included pneumonia (n=45, 68.2%), extrapulmonary causes (n=12, 18.2%), toxic lung injury (n=3, 4.5%), aspiration of gastric contents (n=3; 4.5%) and unknown causes (n=3, 4.5%). Early hypercapnia was present in 39 of 66 patients (59.1%). All patients required mechanical ventilation. Seven patients (10.6%) were ventilated non-invasively. A total of 19 patients (28.8%) received vv-ECMO. Baseline demographics, clinical characteristics and details on ARDS management stratified by the presence of early hypercapnia are presented in Table 1. Data on new central nervous system disorders at discharge and functional outcome at 3 months are presented in Additional file 3.

**Early hypercapnia**

Cerebrovascular autoregulation was monitored twice in 51 of the 66 patients, and once in 15 patients, resulting in a total of 117 measurement periods. Patients with early hypercapnia showed impaired CVA during 22.95±18.75% of the monitoring period. In patients without early hypercapnia cerebrovascular autoregulatory response was impaired during 27.45±18.51% of the monitoring period (Fig. 2). Mean MAP (74.9 mmHg±9.1 vs. 76.3 mmHg±10.8) and mean COx (0.06±0.18 vs. 0.11±0.15) were similar in patients with and without early hypercapnia. Cerebral oxygenation was higher in patients with early hypercapnia (67.32%±10.20) compared with patients without early hypercapnia (59.81%±12.03). Patients with early hypercapnia had significantly higher mean PaCO₂ (47.8 mmHg±17.9 vs. 41.6 mmHg±8.6, p=0.001) and higher PaCO₂ variability (115.1 mmHg±168.8 vs. 32.1 mmHg±40.3, p<0.001) between ARDS diagnosis and the first CVA assessment compared with patients without early hypercapnia; Table 2. The evolution of PaCO₂ between ARDS onset and CVA assessments is presented in Additional file 4. Additional data on hemodynamic parameters and results from arterial blood gas analyses are listed in Table 2.

Multivariable analysis did not show a significant association between early hypercapnia (PaCO₂ ≥ 50 mmHg with pH < 7.35) and impaired CVA (Table 3). In contrast to normo- and hypercapnia, hypocapnic episodes during measurement were significantly associated with impaired CVA (B=0.155 [95% CI 0.014; 0.296], p=0.032); Fig. 3. Other variables included in the model for a potentially confounding influence (vv-ECMO, sedation, ARDS severity, age, ARDS etiology) were not significantly associated with impaired CVA (Table 3 and Additional file 5).

The sensitivity analysis did not show a significant association between early hypercapnia (PaCO₂ ≥ 60 mmHg) and impaired CVA (Additional file 6a). In contrast to normo- and hypercapnia, hypocapnic episodes during measurement were significantly associated with impaired CVA (B=0.186 [95% CI 0.072; 0.300], p=0.002). Other variables included in the model for a potentially confounding influence (age and ARDS etiology) were not significantly associated with impaired CVA (Additional file 6a).

To assess the potential effect of PaCO₂ changes on CVA impairment, we used another linear mixed model with the difference in PaCO₂ between ARDS diagnosis and the time of CVA assessment (Additional file 6b). There was no significant association of the delta PaCO₂ with impaired CVA. Compared with normo- and hypercapnia, hypocapnia during CVA measurement was significantly associated with impaired CVA.

**Extracorporeal membrane oxygenation**

Cerebrovascular autoregulation was compared between 19 patients with vv-ECMO, and 47 patients without vv-ECMO. Mean COx and the time with impaired CVA were similar between vv-ECMO and non-ECMO patients (Additional file 7). Patients with vv-ECMO had higher cerebral oxygenation (rSO₂ = 67.32%±10.96) than patients without vv-ECMO (rSO₂ = 63.21%±11.6). In seven patients, who received vv-ECMO during the course of the disease, CVA was measured before and after vv-ECMO initiation. Results from these paired monitoring episodes are shown in Additional file 8.

**Discussion**

The aim of this prospective observational study was to compare CVA during the acute phase of ARDS between patients with and without early hypercapnia. We found that early hypercapnia was not associated with impaired CVA. However, we observed a significant association between hypocapnia during the acute phase of ARDS and impaired CVA.

Early hypercapnia has been shown to be associated with adverse outcome after ARDS [8, 9]. Previous clinical trials that investigated CVA in ARDS focused primarily on the influence of PEEP rather than CO₂ [26, 27]. While Yang et al. did not specifically address the cerebrovascular effects of PaCO₂, Schramm et al. reported
Table 1  Baseline demographic and clinical characteristics and details on the management of acute respiratory distress syndrome (ARDS)

|                      | No early hypercapnia (n = 27) | Early hypercapnia (n = 39) | p     |
|----------------------|-------------------------------|----------------------------|-------|
| Age, years           | 62 ± 17                       | 55 ± 15                    | 0.040 |
| Gender (female)      | 5 (18.5)                      | 9 (23.1)                   | 0.765 |
| Body mass index      | 26.8 ± 4.4                    | 30.8 ± 11.3                | 0.334 |
| Comorbid conditions  |                               |                            |       |
| Arterial hypertension| 10 (37.0)                     | 16 (41.0)                  | 0.802 |
| Diabetes             | 1 (3.7)                       | 8 (20.5)                   | 0.071 |
| Coronary heart disease| 3 (11.1)                    | 7 (17.9)                   | 0.508 |
| Arrhythmia           | 7 (25.9)                      | 3 (7.7)                    | 0.077 |
| Chronic obstructive pulmonary diseasea | 2 (7.4) | 6 (15.4) | 0.455 |
| Asthma               | 0 (0.0)                       | 2 (5.1)                    | 0.509 |
| Malignant hematologic disease | 7 (25.9) | 3 (7.7) | 0.077 |
| Autoimmune disease   | 3 (11.1)                      | 2 (5.1)                    | 0.393 |
| Solid organ transplantation | 2 (7.4) | 2 (5.1) | 1.000 |
| AIDS                 | 0 (0.0)                       | 1 (2.6)                    | 1.000 |
| ARDS severity        |                               |                            | 0.397 |
| Mild                 | 4 (14.8)                      | 6 (15.4)                   |       |
| Moderate             | 14 (51.9)                     | 14 (35.9)                  |       |
| Severe               | 9 (33.3)                      | 19 (48.7)                  |       |
| ARDS etiology        |                               |                            | 0.136 |
| Community-acquired pneumonia | 9 (33.3) | 19 (48.7) |       |
| Hospital-acquired pneumonia | 11 (40.7) | 6 (15.4) |       |
| Aspiration           | 1 (3.7)                       | 2 (5.1)                    |       |
| Toxic                | 2 (7.4)                       | 1 (2.6)                    |       |
| Extrapulmonary       | 4 (14.8)                      | 8 (20.5)                   |       |
| Unknown              | 0 (0.0)                       | 3 (7.7)                    |       |
| ARDS etiology        |                               |                            | 0.020 |
| Community-acquired   | 12 (44.4)                     | 29 (74.4)                  |       |
| Hospital-acquired    | 15 (55.5)                     | 10 (25.6)                  |       |
| SOFA scoreb          | 9 ± 4                         | 10 ± 3                     | 0.854 |
| Mechanical ventilation|                             |                            |       |
| Non-invasive ventilation | 7 (25.9)     | 0 (0.0)            | < 0.001 |
| Invasive ventilation  | 20 (74.1)                     | 39 (100)                   |       |
| Respiratory rate, breaths per min | 25 ± 5       | 21 ± 6             | < 0.001 |
| Tidal volume, ml     | 434 ± 185                     | 395 ± 133                  | 0.485 |
| Difference from ideal tidal volume, ml | 19 ± 192 | − 36 ± 142 | 0.264 |
| Positive end-expiratory pressure, mbar | 10 ± 4       | 13 ± 4             | 0.001 |
| Driving pressure, mbar| 15 ± 4                      | 14 ± 3                     | 0.231 |
| Sedation             |                               |                            | 0.048 |
| Intravenousd         | 13 (48.1)                     | 17 (43.6)                  |       |
| Inhalationalt        | 0 (0.0)                       | 2 (5.1)                    |       |
| Mixedd               | 10 (37.0)                     | 20 (51.3)                  |       |
| None                 | 4 (14.8)                      | 0 (0.0)                    |       |
| Adjunctive therapy   |                               |                            |       |
| Prone position       | 11 (40.7)                     | 14 (35.9)                  | 0.798 |
| Inhaled nitric oxide | 6 (22.2)                      | 9 (23.1)                   | 1.000 |
| Veno-venous ECMO     | 3 (11.1)                      | 16 (41.0)                  | 0.012 |

Data are given in n (%) or mean ± SD

ECMO extracorporeal membrane oxygenation

a Without chronic hypercapnia

b Highest score during measurement of cerebrovascular autoregulation

c Ideal tidal volume was defined as 6 ml/kg of ideal body weight

d Continuous administration of propofol or midazolam

e Inhalational application of isoflurane

f Propofol plus isoflurane or midazolam plus isoflurane
that hypercapnia was not associated with impaired CVA, which is similar to our results.

We found that hypocapnia during measurement was associated with impaired CVA. Interestingly, in a large retrospective registry analysis, Cavayas et al. found the rate of PaCO2 reduction upon ECMO initiation to be associated with neurological complications in patients with severe respiratory failure [10]. The risk for ischemic stroke, intracerebral hemorrhage, seizures, and brain death increased with the magnitude of PaCO2 correction within 24 h after ECMO initiation [10]. Similar results were reported in a retrospective single-center study [28]. In 135 patients on vv-ECMO for severe respiratory failure, rapid correction of hypercapnia was associated with intracranial bleeding [28]. We did not find a significant association of the difference in PaCO2 between ARDS diagnosis and CVA assessment and impaired CVA. However, we did not analyze the effect of hypercapnia reduction on CVA.

There are conflicting results on the effect of hypocapnia on CVA in pathologies other than ARDS. While hypocapnia has been shown to promote the impairment of CVA in patients with acute brain injury [29], other studies found no adverse effect of transient hypocapnia on CVA in healthy adults and other neurocritical care patients [30–33].

When interpreting the conflicting results on the effects of CO2 on CVA, it is important to differentiate between the diverse patient populations, as well as different definitions of hypo-, normo- and hypercapnia. This may limit the generalizability of results from single trials. Furthermore, the duration of hyper- and hypocapnia has to be considered when analyzing potential effects of CO2 on CVA. In patients with ARDS, alterations of PaCO2 are mainly driven by respiratory failure or ventilation strategies including low tidal volumes and permissive hypercapnia. Due to our strictly observational study design, we did not actively change PaCO2. Therefore, hyper- or hypocapnia had been present for a period of several hours up to 6 days before measurement. In contrast, studies in healthy subjects and neurocritical care patients included interventional modifications of ventilator settings or spontaneous inhalation of CO2 [29, 31, 33]. In these trials, there was little time delay between reaching the target PaCO2 and the measurement of CVA. Muijzelaar et al. observed that the vasoconstrictive effect of hyperventilation decreases over time. They showed that cerebral vessels returned to their baseline diameter after 20 h of hyperventilation [34]. One can assume that the effects of CO2 on vascular tone become apparent early after elevation or reduction of PaCO2 and that the cerebral vasculature adapts to intermediate or long-term alterations of PaCO2.

In our study, almost 60% of patients presented with early hypercapnia, which is higher than reported previously [9]. Notably, Nin et al. found a 22% prevalence of early hypercapnia in patients with ARDS [9]. The different prevalence may be caused by two main factors: we defined early hypercapnia within the first 24 h of ARDS diagnosis, while Nin et al. assessed hypercapnia during the first 48 h of mechanical ventilation [9]. Importantly, we used protective ventilation with tidal volumes of ≤6 ml/kg of IBW. In contrast, Nin et al. performed a secondary analysis of data from three clinical trials that were published between 2002 and 2013 [35–37]. Mean tidal volumes in these trials were substantially higher with up to 10 ml/kg of IBW, probably reflecting the gradual implementation of the concept of low tidal volumes and permissive hypercapnia into clinical practice.

We observed higher cerebral oxygenation in patients with early hypercapnia compared to patients without early hypercapnia. This finding might be attributable to the vasodilatory effect of CO2 leading to an increase in cerebral blood flow and cerebral tissue oxygenation [11]. Of note, patients with early hypercapnia received sedation with isoflurane more frequently. Volatile anesthetics such as isoflurane are characterized by cerebral vasodilatory properties that may contribute to higher cerebral oxygenation in patients with early hypercapnia [38].
Our study was primarily designed to assess the effect of early hypercapnia on CVA in patients with ARDS. It is important to note that CO₂ does not only influence cerebral vascular tone, but also other organ systems. Among others, hyper- and hypocapnia are associated with the severity of respiratory failure, compromised immune response, and impaired right ventricular function [8, 39].

Limitations and strengths
There are several limitations to this observational trial. First, spontaneously breathing patients without sedation were more likely to have higher respiratory rates and lower PaCO₂. We did consider the type of sedation as a potential confounder in the multivariable analysis and did not find a significant association between type of sedation and CVA. However, anesthetics are known to affect

Table 2 Hemodynamic parameters and selected results from blood gas analyses during the measurement of cerebrovascular autoregulation (CVA)

| Parameter                              | No early hypercapnia (n = 27) | Early hypercapnia (n = 39) |
|----------------------------------------|-------------------------------|-----------------------------|
| Time with impaired CVA (%)            | 27.45 ± 18.51                 | 22.95 ± 18.75               |
| Duration of measurement (min)         | 77 ± 12                       | 77 ± 15                     |
| Time with impaired CVA (min)          | 21 ± 15                       | 18 ± 15                     |
| Cerebral oxygenation index COx        | 0.11 ± 0.15                   | 0.06 ± 0.18                 |
| Regional cerebral oxygen saturation rSO₂ (%) | 59.81 ± 12.03               | 67.32 ± 10.20               |
| Mean arterial blood pressure (mmHg)   | 76.34 ± 10.84                 | 74.85 ± 9.12                |
| Heart rate (bpm)                      | 81.25 ± 18.80                 | 90.45 ± 19.10               |
| Body temperature (°C)                 | 37.1 ± 0.8                    | 37.1 ± 0.9                  |
| Hemoglobin (mg dl⁻¹)                  | 9.20 ± 1.42                   | 9.79 ± 1.63                 |
| PaO₂/FiO₂ ratio                       | 152.55 ± 57.16                | 151.38 ± 75.27              |
| Mean PaO₂ (mmHg)                      | 80.6 ± 18.4                   | 85.9 ± 16.4                 |
| Mean PaCO₂ (mmHg)                     | 45.2 ± 11.1                   | 47.7 ± 9.6                  |
| Hypocapnia (< 35 mmHg)b               | 8 (17)                        | 3 (4.3)                     |
| Normocapnia (35–50 mmHg)b             | 28 (59.6)                     | 43 (61.4)                   |
| Hypercapnia (> 50 mmHg)b              | 11 (23.4)                     | 24 (34.3)                   |
| pH                                     | 7.41 ± 0.08                   | 7.39 ± 0.09                 |
| Lactate (mmol/L)                      | 1.6 ± 0.9                     | 2.3 ± 2.5                   |
| Δ PaCO₂ (mmHg)c                       | 1.29 ± 1.76                   | 1.79 ± 3.23                 |
| Δ pHc                                  | 0.01 ± 0.02                   | 0.01 ± 0.02                 |
| Δ PaO₂/FiO₂ ratio (mmHg)c             | 8.20 ± 12.86                  | 9.86 ± 19.73                |
| Isoflurane (ml/h)                     | 6.5 ± 4.5                     | 6.8 ± 4.1                   |
| Isoflurane (end-tidal concentration in %) | 1.1 ± 0.4                    | 1.2 ± 0.3                   |

Mean values from monitoring episodes 1 and 2, stratified by the presence of early hypercapnia. Data are given in n (%) or mean ± SD

COx cerebral oxygenation index as a surrogate of cerebrovascular autoregulation

a “Mean PaCO₂” refers to the statistical mean of two blood gas analyses during one CVA monitoring episode

b PaCO₂ was categorized as “hypocapnia”, “normocapnia”, and “hypercapnia” during each measurement period
c Δ values refer to the mean difference between the first and the second CVA measurement in one study participant
d Calculated as the variance

...
cerebrovascular tone as well as CVA. We cannot rule out that a statistical effect did not become apparent because of our relatively small sample size. The same applies for vv-ECMO therapy, which was not significantly associated with impaired CVA in our study. Importantly, the impact of vv-ECMO on CVA remains unclear [40]. Having said that, it is noteworthy that we used veno-venous flow in all patients requiring ECMO, which is supposed to have less impact on cerebral blood flow than ECMO with veno-arterial flow [41].

Second, there are several methods for the continuous measurement of CVA that differ with regard to the assessment of cerebral blood flow. Non-invasive approaches include transcranial Doppler sonography and near-infrared spectroscopy [24]. We chose the latter approach, which has been validated thoroughly [42, 43]. However, differences in methodological approaches lead to a limited comparability between study results. We continuously analyzed CVA during a 60–90 min period during the acute phase of ARDS. PaCO2 was determined twice during CVA assessment. There were no substantial fluctuations of PaCO2 during CVA monitoring. However, we observed a high variability of PaCO2 between the diagnosis of ARDS and CVA assessment that was significantly higher in patients with early hypercapnia. By choosing CVA assessment within predefined time periods of 60–90 min, we may have missed relevant fluctuations of PaCO2. This limitation highlights the need for future studies using continuous CVA monitoring throughout the course of disease.

Two-channel near-infrared spectroscopy used in this study provides information on cerebral oxygenation in the area of the frontal cortex. Oxygenation of other cerebral lobes and deeper brain structures is not reflected by near-infrared spectroscopy [44].

Third, volatile anesthetics including isoflurane may have a profound effect on cerebrovascular tone resulting in a substantial impact on CVA [45]. Although we have included the type of sedation as a potential confounder in the multivariable analysis, the cerebrovascular effects of isoflurane may have biased the results of our study.

---

**Table 3** Linear mixed model—estimates of fixed effects

| Parameter | Estimate | 95% CI—low | 95% CI—up | p   |
|-----------|----------|------------|-----------|-----|
| Intercept | 0.177    | −0.059     | 0.414     | 0.139 |
| No early hypercapnia | 0.023 | −0.054 | 0.100 | 0.556 |
| Sedation |          |            |           |     |
| Mixed sedation (vs. no sedation) | −0.042 | −0.217 | 0.133 | 0.635 |
| Intravenous sedation (vs. no sedation) | −0.074 | −0.235 | 0.087 | 0.363 |
| Inhalational sedation (vs. no sedation) | −0.076 | −0.260 | 0.107 | 0.410 |
| ARDS severity |          |            |           |     |
| Mild (vs. severe) | 0.032 | −0.062 | 0.126 | 0.498 |
| Moderate (vs. severe) | −0.018 | −0.102 | 0.065 | 0.663 |
| Age (per year increase) | 0.001 | −0.001 | 0.004 | 0.275 |
| Hypocapnia during the measurement perioda | 0.155 | 0.037 | 0.276 | 0.032 |
| ARDS etiology (community-acquired vs. hospital-acquired)b | 0.047 | −0.027 | 0.122 | 0.208 |

The variables position (prone vs. supine), inhalational nitric oxide, extracorporeal membrane oxygenation, and the Sequential Organ Failure Assessment score during measurement were included in the initial model and eliminated during the stepwise-backwards reduction.

ARDS: acute respiratory distress syndrome

a Vs. Normo- and hypercapnia
b Etiologies were categorized as "community-acquired" and "hospital-acquired" for the linear mixed model.

---

![Fig. 3](image-url)

**Fig. 3** Cerebrovascular autoregulation and carbon dioxide during measurement periods. The time with impaired cerebrovascular autoregulation (CVA, in % of the total monitoring time) is shown for patients with hypocapnia (PaCO2 < 35 mmHg), normocapnia (PaCO2 35–50 mmHg) and hypercapnia (PaCO2 > 50 mmHg) during the measurement of CVA. Data are presented as median (boxes) with Tukey whiskers.
Since the definition of hypercapnia varies between studies, we performed a sensitivity analysis using a higher threshold for early hypercapnia (PaCO₂ ≥ 60 mmHg). This confirmed our initial findings and did not reveal an association between early hypercapnia and impaired CVA. Impairment of CVA has been linked with poor neurocognitive outcome and mortality in patients without structural central nervous system lesions [14, 43]. This study focused on the association between alterations of PaCO₂ during the acute phase of ARDS and CVA. Future research should assess the effect on CVA impairment on functional neurological outcome after ARDS.

Conclusions
In the present study, we did not observe an adverse impact of hypercapnia during the acute phase of ARDS on CVA. However, we found that hypocapnia is associated with impaired CVA. Our findings suggest that moderate hypercapnia during the acute phase of ARDS may be safe with regard to CVA and hypercapnia may be tolerated to a certain extent to achieve low tidal volumes, whereas episodes of hypocapnia may compromise cerebral blood flow regulation.

Abbreviations
ARDS: Acute respiratory distress syndrome; CO₂: Carbon dioxide; COx: Cerebral oxygenation index; CVA: Cerebrovascular autoregulation; vv-ECMO: Veno-venous extracorporeal membrane oxygenation; IBW: Ideal body weight; MAP: Mean arterial blood pressure; PaCO₂: Arterial partial pressure of carbon dioxide.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13613-021-00831-7.

Acknowledgements
Not applicable.

Authors’ contributions
UK: conception and design of the work; acquisition, analysis, and interpretation of data; writing original draft. YY: acquisition, analysis, and interpretation of data. AN: design of the work; interpretation of data; substantial revision of the manuscript. MF: conception and design of the work; acquisition, analysis, and interpretation of data; writing original draft. All authors have approved the submitted version (and any substantially modified version that involves the author’s contribution to the study), and have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. Ursula Kahl is funded by the Clinician Scientist Program of the University of Hamburg. The University of Hamburg was not involved in any of the following: study design, conduct of the research, preparation of this manuscript, analysis and interpretation of data; writing of the report; decision to submit the article for publication. Marlene Fischer receives financial support from the Johanna und Fritz Buch Gedächtnis-Stiftung. The Johanna und Fritz Buch Gedächtnis-Stiftung was not involved in any of the following: study design, conduct of the research, preparation of this manuscript, analysis and interpretation of data; writing of the report; decision to submit the article for publication.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Ethical approval for this study (serial number PV5872) was obtained from the ethics committee of the Hamburg Chamber of Physicians on November 8th, 2018. Oral and written informed consent were obtained from the patient or legal guardian.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
References
1. ARDS Definition Task Force. Acute respiratory distress syndrome: the berlin definition. J Am Med Assoc. 2012;307:2526–33.
2. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315:788.
3. Bein T, Weber-Carstens S, Apeflbacher C. Long-term outcome after the acute respiratory distress syndrome: different from general critical illness? Curr Opin Crit Care. 2018;24:35–40.
4. Hickling KG, Henderson SJ, Jackson R. Low mortality associated with low volume pressure limited ventilation with permissive hypercapnia in severe adult respiratory distress syndrome. Intensive Care Med. 1990;16:372–7.
5. Amato MB, Barbos CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med. 1999;338:347–54.
6. Briva A, Vadavó J, Lecuona E, Welch LC, Chen J, Dada LA, et al. High CO2 levels impair alveolar epithelial function independently of pH. PLoS ONE. 2007;2:e138.
7. Doer CH, Gajic O, Berrios JC, Caples S, Abdel M, Lynn JF, et al. Hypercapnic acidosis impairs plasma membrane wound resealing in ventilator-injured lungs. Am J Respir Crit Care Med. 2005;171:1371–71.
8. Morales-Quintana L, Campriú-Bimbals M, Bringué J, Bos LD, Schultz ML, Artigas A. The role of hypercapnia in acute respiratory failure. Intensive Care Med Exp. 2019;7:39.
9. Nin N, Muriel A, Peruelas O, Brochard L, Lorente JA, Ferguson ND, et al. Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome. Intensive Care Med. 2017;43:200–8.
10. Cavayas YA, Munshi L, Del Sorbo L, Fan E. The early change in PaCO2 after extracorporeal membrane oxygenation initiation is associated with neurolological complications. Am J Respir Crit Care Med. 2020;201:1525–35.
11. Meng L, Gelb AW. Regulation of cerebral autoregulation by carbon dioxide. Anesthesiology. 2015;122:196–205.
12. Lassen NA. Cerebral blood flow and oxygen consumption in man. Physiol Rev. 1959;39:183–238.
13. Donnelly, J Budhosoksi KP, Smielewski P, Czosnyka M. Regulation of the cerebral circulation: bedside assessment and clinical implications. Crit Care. 2016;20:129.
14. Crippa IA, Subirà C, Vincent J-L, Fernandez RF, Hernandez SC, Cavicchi FZ, et al. Impaired cerebral autoregulation is associated with brain dysfunction in patients with sepsis. Crit Care Lond Engl. 2018;22:327.
15. Rivera-Lara L, Zorrilla-Vaca A, Geocadin R, Ziai W, Healy R, Thompson R, et al. Cerebral blood flow autoregulation in sepsis for the intensivist: why its monitoring may be the future of individualized care. J Intensive Care Med. 2018;33:63–73.
16. Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195:1253–63.
17. Fichtner F, Moerer O, Weber-Carstens S, Nothacker M, Kaisers U, Laudi S, et al. Clinical guideline for treating acute respiratory insufficiency with invasive ventilation and extracorporeal membrane oxygenation: evidence-based recommendations for choosing modes and setting parameters of mechanical ventilation. Respir Int Rev Thorac Dis. 2019;98:357–72.
18. Karagiannidis C, Bein T, Weber-Carstens S. Indications and limitations of ECMO therapy: considerations on evidence, treatment decisions and ethical challenges. Med Klin Intensivmed Notfallmedizin. 2019;114:207–13.
19. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI). S3-Leitlinie Invasive Beatmung und Einsatz extrakorporaler Verfahren bei akuter respiratorischer Insuffizienz. AWMF Leitlinien-Regist Nr 00102. 2017.
20. Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol. 2011;6:147–63.
21. Beck S, Ragab H, Hoop D, Meißner-Schmitt A, Rademencher C, Kahl U, et al. Comparing the effect of positioning on cerebral autoregulation during radical prostatectomy—a prospective observational study. J Clin Monit Comput. 2020. https://doi.org/10.1007/s10887-020-00594-0.
22. Xiong L, Liu X, Shang T, Smielewski P, Donnelly J, Guo Z, et al. Impaired cerebral autoregulation: measurement and application to stroke. J Neurol Neurosurg Psychiatry. 2017;88:520–31.
23. Zweifel C, Dias C, Smielewski P, Czosnyka M. Continuous time-domain monitoring of cerebral autoregulation in neurocritical care. Med Eng Phys. 2014;36:638–45.
24. Hon D, Brown C, Ono M, Rappold T, Sieber F, Gottschalk A, et al. Arterial pressure above the upper cerebral autoregulation limit during cardiopulmonary bypass is associated with postoperative delirium. Br J Anesth. 2014;113:1009–17.
25. Schramm P, Closden D, Feltel M, Berres M, Klein Kl, David M, et al. Influence of PEEP on cerebral blood flow and cerebrovascular autoregulation in patients with acute respiratory distress syndrome. J Neurosurg Anesth. 2013;25:162–7.
26. Yang C, Chen Z, Lu Y, He H, Zeng W. The influence of positive end-expiratory pressure on cerebral blood flow and cerebrovascular autoregulation in patients with acute respiratory distress syndrome. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2014;26:335–8.
27. Luyt C-E, Brechot N, Demondon P, Iovananic T, Hékimian G, Lebretion G, et al. Brain injury during venovenous extracorporeal membrane oxygenation. Intensive Care Med. 2016;42:897–907.
28. Cold GE, Christensen MS, Schmidt K. Effect of two levels of induced hypocapnia on cerebral autoregulation in the acute phase of head injury coma. Acta Anaesthesiol Scandin. 1981;25:397–401.
29. Moller K, Sinha P, Knudsen GM, Larsen FS. Effect of short-term hyperventilation on cerebral blood flow autoregulation in patients with acute bacterial meningitis. Stroke. 2000;31:1116–22.
30. Aaslid R, Lindegaard KF, Sorteberg W, Nornes H. Cerebral autoregulation dynamics in humans. Stroke. 1989;20:45–52.
31. Newell DW, Weber JP, Watson R, Aaslid R, Wynn HR. Effect of transient moderate hyperventilation on dynamic cerebral autoregulation after severe head injury. Neurosurgery Oxford Academic. 1996;39:35–44.
32. Zhong Bing Ji Jiu Yi Xue. 2014;26:335–8.
33. Muizelaar JP, van der Poel HG, Li ZC, Kontos HA, Levasseur JE. Pial arteriovenous malformations and mortality for patients with acute respiratory distress syndrome. J Am Med Assoc. 1998;280:397–402.
34. Muizelaar JP, van der Poel HG, Li ZC, Kontos HA, Levasseur JE. Pial arteriovenous malformations and mortality for patients with acute respiratory distress syndrome. J Am Med Assoc. 1998;280:397–402.
35. Esteban A, Anzueto A, Frutos F, Alía I, Brochard L, Stewart TE, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA. 2000;283:345–55.
36. Esteban A, Ferguson ND, Meade MO, Frutos-Vivar F, Apezteguia C, Brochard L, et al. Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med. 2008;177:170–7.
37. Esteban A, Frutos-Vivar F, Muriel A, Ferguson ND, Peruelas O, Abraira V, et al. Evolution of mortality over time in patients receiving mechanical ventilation. Am J Respir Crit Care Med. 2013;188:220–30.
38. Iida H, Ohata H, Iida M, Watanabe Y, Dohi S. Isolflurane and sevoflurane induce vasodilation of cerebral vessels via ATP-sensitive K+ channel activation. Anesthesiology. 1998;89:954–60.
39. Nentwich J, John S. Current techniques for extracorporeal decarboxylation. Med Klin Intensivmed Notfallmedizin. 2019;114:733–40.
40. Kazmi SQ, Sivakumar S, Karakitsos D, Alharthy A, Lazaridis C. Cerebral pathophysiology in extracorporeal membrane oxygenation: pitfalls in daily clinical management. Crit Care Res Pract. 2018. https://doi.org/10.1155/2018/9237810.

41. Hunter C, Blood A, Bishai J, Hickerson A, Wall D, Peverini R, et al. Cerebral blood flow and oxygenation during venaarterial and venovenous extracorporeal membrane oxygenation in the newborn lamb. Pediatr Crit Care Med. 2004;5:475–81.

42. Ono M, Zheng Y, Joshi B, Sigl JC, Hogue CW. Validation of a stand-alone near-infrared spectroscopy system for monitoring cerebral autoregulation during cardiac surgery. Anesth Analg. 2013;116:198–204.

43. Rivera-Lara L, Geocadin R, Zorrilla-Vaca A, Healy R, Radzik RR, Palmisano C, et al. Validation of near-infrared spectroscopy for monitoring cerebral autoregulation in comatose patients. Neurocrit Care. 2017;27:362–9.

44. Steppan J, Hogue CW. Cerebral and tissue oximetry. Best Pract Res Clin Anaesthesiol. 2014;28:429–39.

45. Slupe AM, Kirsch JR. Effects of anesthesia on cerebral blood flow, metabolism, and neuroprotection. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2018;38:2192–208.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.